Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

21. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer Dacomitinib for untreated EGFR Dacomitinib for untreated EGFR mutation-positiv mutation-positive non-small-cell lung e non-small-cell lung cancer cancer T echnology appraisal guidance Published: 14 August 2019 www.nice.org.uk/guidance/ta595 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

22. The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis

The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis The optimal treatment for stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis.We performed a search of electronic databases for randomized controlled trials comparing the following treatments: surgery, radiotherapy, chemotherapy, and their multiple combinations before March 25, 2018. Pooled data on overall

2019 EvidenceUpdates

23. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. (PubMed)

Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Decreased exercise capacity and health-related quality of life (HRQoL) are common in people following lung resection for non-small cell lung cancer (NSCLC). Exercise training has been demonstrated to confer gains in exercise capacity and HRQoL for people with a range of chronic conditions, including chronic obstructive pulmonary disease and heart failure, as well as in people with prostate (...) and breast cancer. A programme of exercise training may also confer gains in these outcomes for people following lung resection for NSCLC. This systematic review updates our 2013 systematic review.The primary aim of this review was to determine the effects of exercise training on exercise capacity and adverse events in people following lung resection (with or without chemotherapy) for NSCLC. The secondary aims were to determine the effects of exercise training on other outcomes such as HRQoL, force

2019 Cochrane

24. Interventions for smoking cessation in people diagnosed with lung cancer. (PubMed)

Interventions for smoking cessation in people diagnosed with lung cancer. Lung cancer is one of the most common causes of death from cancer worldwide. Smoking induces and aggravates many health problems, including vascular diseases, respiratory illnesses and cancers. Tobacco smoking constitutes the most important risk factor for lung cancer. Most people with lung cancer are still active smokers at diagnosis or frequently relapse after smoking cessation. Quitting smoking is the most effective (...) way for smokers to reduce the risk of premature death and disability. People with lung cancer may benefit from stopping smoking. Whether smoking cessation interventions are effective for people with lung cancer and whether one method of quitting is more effective than any other has not been systematically reviewed.To determine the effectiveness of smoking cessation programmes for people with lung cancer.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (accessed via

2019 Cochrane

25. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lung cancer (NSCLC) after 1 year of treatment. The JO25567 phase 2 trial comparing erlotinib plus bevacizumab

2019 EvidenceUpdates

26. Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial

Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial Lung cancer is associated with poor health-related quality of life (HRQoL) and high symptom burden. This trial aimed to assess the efficacy of home-based rehabilitation versus usual care in inoperable lung cancer.A parallel-group, assessor-blinded, allocation-concealed, randomised controlled trial. Eligible participants were allocated (1:1) to usual care (UC) plus 8 weeks of aerobic (...) found for HRQoL (Functional Assessment of Cancer Therapy-Lung: 13.0 (3.9 to 22.1), p=0.005) and symptom severity (MD Anderson Symptom Inventory-Lung Cancer: -2.2 (-3.6 to -0.9), p=0.001).Home-based rehabilitation did not improve functional exercise capacity but there were improvements in patient-reported exploratory secondary outcomes measures observed at 6 months.Australian New Zealand Clinical Trials Registry (ACTRN12614001268639).© Author(s) (or their employer(s)) 2019. No commercial re-use. See

2019 EvidenceUpdates

27. Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis

Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis It is important to develop a surgical technique to reduce dissemination of tumor cells into the blood during surgery.To compare the outcomes of different sequences of vessel ligation during surgery on the dissemination of tumor cells and survival in patients with non-small (...) cell lung cancer.This multicenter, randomized clinical trial was conducted from December 2016 to March 2018 with patients with non-small cell lung cancer who received thoracoscopic lobectomy in West China Hospital, Daping Hospital, and Sichuan Cancer Hospital. To further compare survival outcomes of the 2 procedures, we reviewed the Western China Lung Cancer database (2005-2017) using the same inclusion criteria.Vein-first procedure vs artery-first procedure.Changes in folate receptor-positive

2019 EvidenceUpdates

28. Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) Published 10 June 2019 1 SMC2147 brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) Takeda UK Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows (...) : ADVICE: following a full submission assessed under the end-of-life and ultra-orphan medicine process brigatinib (Alunbrig®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. Brigatinib was associated with an objective response rate of 56% in a single-arm, open- label, phase II study in patients with ALK

2019 Scottish Medicines Consortium

29. Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)

Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) Published 10 June 2019 1 SMC2156 durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) AstraZeneca 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) considered under the ultra-orphan and end of life process durvalumab (Imfinzi®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on =1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. Durvalumab, compared with placebo, improved progression-free survival and overall

2019 Scottish Medicines Consortium

30. Paclitaxel (Pazenir) - metastatic breast cancer, non-small cell lung cancer

Paclitaxel (Pazenir) - metastatic breast cancer, non-small cell lung cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/159292/2019 EMEA/H/C/004441 Pazenir (paclitaxel (...) ) An overview of Pazenir and why it is authorised in the EU What is Pazenir and what is it used for? Pazenir is used to treat the following cancers in adults: • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body; • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin

2019 European Medicines Agency - EPARs

31. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer Atezolizumab in combination for treating Atezolizumab in combination for treating metastatic non-squamous non-small-cell metastatic non-squamous non-small-cell lung cancer lung cancer T echnology appraisal guidance Published: 5 June 2019 www.nice.org.uk/guidance/ta584 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

32. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. (PubMed)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment (...) with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater

2019 Lancet

33. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Durvalumab for treating locally advanced Durvalumab for treating locally advanced unresectable non-small-cell lung cancer unresectable non-small-cell lung cancer after platinum-based chemor after platinum-based chemoradiation adiation T echnology appraisal guidance Published: 1 May 2019 www.nice.org.uk/guidance/ta578 © NICE 2019. All rights reserved. Subject to Notice of rights (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum- based

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

34. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. (PubMed)

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lung cancer (NSCLC).Clinical data from EHRs were linked with CGP results for 28 998 patients (...) EHRs.Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy.Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0

2019 JAMA

35. Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Alectinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (neues Anwendungsgebiet) (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A17-67 Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 (new therapeutic indication) Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lung cancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

36. Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67

Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67 1 Translation of addendum A18-30 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-67 (Version 1.0; Status: 1 June 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 1 June 2018 1.0 Commission: A18-30 Version: Status: IQWiG Reports – Commission No. A18-30 (...) Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 1 Addendum A18-30 Version 1.0 Alectinib – Addendum to Commission A17-67 1 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 Commissioning agency: Federal Joint Committee Commission awarded on: 8 May 2018 Internal Commission No.: A18-30 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

37. Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50

Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 1 Translation of addendum A18-09 Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-50 (Version 1.0; Status: 23 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 23 February 2018 1.0 Commission: A18-09 Version: Status: IQWiG Reports (...) – Commission No. A18-09 Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 1 Addendum A18-09 Version 1.0 Atezolizumab – Addendum to Commission A17-50 23 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 Commissioning agency: Federal Joint Committee Commission awarded on: 5 February 2018

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

38. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why (...) it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer

2019 European Medicines Agency - EPARs

39. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib Brigatinib for treating ALK Brigatinib for treating ALK-positiv -positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer after crizotinib after crizotinib T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta571 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

40. Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. (PubMed)

Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. Pulmonary complications are often seen during the postoperative period following lung resection for patients with lung cancer. Some situations such as intubation, a long stay in the intensive care unit, the high cost of antibiotics and mortality may be avoided with the prevention of postoperative pulmonary complications. Non-invasive positive pressure ventilation (NIPPV (...) ) is widely used in hospitals, and is thought to reduce the number of pulmonary complications and mortality after this type of surgery. Therefore, a systematic review is needed to critically assess the benefits and harms of NIPPV for patients undergoing lung resection. This is an update of a Cochrane review first published in 2015.To assess the effectiveness and safety of NIPPV for preventing complications in patients following pulmonary resection for lung cancer.We searched the Cochrane Central Register

2019 Cochrane